Cancer clinical trials in the region Auvergne-Rhône-Alpes
342 currently recruiting clinical trials
Looking for clinical trials?
Clinical trial search is a complex process, with countless criteria to consider. Our AI assistant navigates this complexity with precise, expert-level analysis of the most relevant trials based on your medical profile. Our database is fully up to date, so you see only actively recruiting sites. It's fast and easy:
- Create your account
- Copy-paste your latest medical report
- Our AI-based assistant does the rest for you
Whether you are a patient or a doctor, create an account to find and apply for the most relevant clinical trials:
Phase 3
Lung cancer
#NCT05215340
#2023-507933-12-00
NSCLC (Non-Small Cell Lung Cancer)
Locally Advanced
Metastatic
PDL1 Positive (>= 50%)
None
Systemic Treatment-Naive
ALK
BRAF
EGFR
MET
NTRK-1/2/3
RET
ROS-1
Immunotherapy
Targeted therapy
Antibody Drug Conjugates (ADC)
Immunotherapy
Chemotherapy
Targeted therapy
Antibody Drug Conjugates (ADC)
Centre Léon Bérard (Lyon)
Daiichi Sankyo
Phase 3
Lung cancer
#NCT05899608
#2024-513087-26-00
NSCLC (Non-Small Cell Lung Cancer)
Squamous NSCLC
Non-squamous NSCLC
Metastatic
None
Systemic Treatment-Naive
Hôpital Lyon Sud - Hospices Civils de Lyon (Pierre-Bénite)
Summit Therapeutics
Phase 3
Lung cancer
#NCT04613596
#2023-508922-83-00
NSCLC (Non-Small Cell Lung Cancer)
Locally Advanced
Metastatic
KRAS G12C
PDL1 Positive (>= 50%)
None
Systemic Treatment-Naive
Centre Hospitalier Universitaire de Grenoble (La Tronche)
Mirati Thérapeutique Inc.
Phase 3
Lung cancer
#NCT06117774
#2023-506235-15-00
SCLC (Small Cell Lung Cancer)
Localized
None
Chemotherapy
Radiotherapy
EGFR
Bispecific T-cell engager antibodies
Hôpitaux Nord-Ouest - Villefranche-sur-Saône (Gleizé)
Amgen
Phase 3
Lung cancer
#NCT06908993
#2024-519971-25-00
NSCLC (Non-Small Cell Lung Cancer)
Locally Advanced
Metastatic
MET
1
2
Immunotherapy
Chemotherapy
ALK
BRAF
EGFR
HER2
KRAS non G12C
RET
ROS-1
Systemic Treatment-Naive
Targeted therapy
Centre Hospitalier de Valence (Valence), Centre Léon Bérard (Lyon), Institut de cancérologie - GHM (Grenoble)
Intergroupe Francophone de Cancérologie Thoracique
Phase 3
Stomach and esophageal cancer
#NCT06901531
#2024-519773-19-00
Stomach
Oesogastric junction
Adenocarcinoma
Locally Advanced
Metastatic
Claudin 18.2
PDL1 Positive (1% <= X < 25%)
PDL1 Positive (25% <= X < 50%)
PDL1 Positive (>= 50%)
None
Systemic Treatment-Naive
HER2
Immunotherapy
Chemotherapy
Hôpital Lyon Sud - Hospices Civils de Lyon (Pierre-Bénite), Hôpital Privé Jean Mermoz - Ramsay Santé (Lyon)
Astellas Pharma Développement mondial, Inc.
Phase 3
Lymphoma
#NCT05947851
#2022-501560-17-01
B cell lymphoma
Lymphocytic lymphoma
None
Treated / Controled
1
2
3 or more
Systemic Treatment-Naive
Targeted therapy
Centre Hospitalier Universitaire de Clermont Ferrand (Clermont-Ferrand)
Merck Sharp & Dohme LLC
Phase 3
CLL & Richter's syndrome
#NCT05947851
#2022-501560-17-01
CLL (Chronic Lymphocytic Leukemia)
None
Treated / Controled
1
2
3 or more
Systemic Treatment-Naive
Targeted therapy
Centre Hospitalier Universitaire de Clermont Ferrand (Clermont-Ferrand)
Merck Sharp & Dohme LLC
Phase 3
Breast cancer
#NCT07060807
HER2 Negative
HR Positive
Locally Advanced
Metastatic
None
1
Targeted therapy
Hormone therapy
BRCA 1/2
Chemotherapy
Centre Léon Bérard (Lyon)
Merck Sharp & Dohme LLC
Phase 3
Lung cancer
#NCT06472245
#2023-509340-10-00
NSCLC (Non-Small Cell Lung Cancer)
Metastatic
1
2
3 or more
Immunotherapy
ALK
EGFR
ROS-1
Systemic Treatment-Naive
Hôpital de la Croix Rousse - Hospices Civils de Lyon (Lyon), Centre Hospitalier Universitaire de Grenoble (La Tronche)
OSE Immunotherapeutics